Pune, Dec. 01, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global erectile dysfunction market is expected to clock US$ 4.30 billion by 2030 and to grow at a CAGR of 8.3% during the forecast period. Owing to the increasing cases of erectile dysfunction cases due to the global rise in the elderly population. This exclusive information is published by Growth Plus Reports in its report titled “Erectile Dysfunction Market – Global Outlook & Forecast 2022-2030”
Download PDF Brochure of Erectile Dysfunction Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/erectile-dysfunction-market/8005
The adoption of a sedentary lifestyle and the stress that goes along with it, the growing geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes are a few factors that propel the erectile dysfunction (ED) medicine industry. The likelihood of erectile dysfunction is significantly increased by a sedentary lifestyle, drunkenness, and smoking. Increased acceptability of such detrimental lifestyle choices could spur market expansion.
The global erectile dysfunction market has been analyzed from three perspectives: drug, distribution channel, and region.
Excerpts from ‘By Drug Segmentation’
Based on type, the global erectile dysfunction market is subdivided into:
The most popular medication used as initial therapy for erectile dysfunction is sildenafil (Viagra). One hour prior to intercourse, sildenafil (Viagra) is most effective when taken on an empty stomach. If you suffer from mild to moderate erectile dysfunction, it remains effective for at least four to five hours. Lupin gained approval from the US Food and Drug Administration (FDA) in March 2019 to market its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg as a generic alternative to Pfizer Inc.'s Viagra Tablets, 25 mg, 50 mg, and 100 mg. So, throughout the course of the projection period, the segment is anticipated to grow due to the success of Viagra (sildenafil citrate) in the treatment of erectile dysfunction.
Excerpts from ‘By Region Segmentation’
Based on region, the global erectile dysfunction market has been segmented into:
Rest of the World
During the projected period, it is anticipated that the market for erectile dysfunction medications in Asia Pacific will expand quickly. The introduction of new items has contributed to the region's growth. For instance, iX Biopharma stated in May 2020 that it would provide Wafesil and Silcap in Australia via telemedicine to treat an adult patient with erectile dysfunction.
Browse Detailed Summary of Research Report with TOC: https://growthplusreports.com/report/erectile-dysfunction-market/8005
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global erectile dysfunction market are:
Eli Lilly and Company
Viatris Specialty LLC
Petros Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Auxilium Pharmaceuticals, Inc.
Vigonvita Life Sciences
RDC Clinical Pty Ltd.
Table of Content
Timeline Under Consideration
Historical Years – 2020
Base Year – 2021
Forecasted Years – 2022 to 2030
Currency Used in the Report
Data Collection Methodology
Market Estimation Approach
Market Forecasting Model
Limitations and Assumptions
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2021)
GLOBAL ERECTILE DYSFUNCTION MARKET - ANALYSIS & FORECAST, BY DRUG
GLOBAL ERECTILE DYSFUNCTION MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
VALUE PROPOSITIONS RELATED TO THE REPORT:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
Distributor Landscape Assessment
Customer Base Assessment
Investment & Initiatives Analysis
'Business Profile' of Key Players
Directly Purchase Premium Copy of Erectile Dysfunction Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=CA1MxrxwXGnDoq6l4SmpRJ0PKaf4rQBWt537ohND&report_id=8005&license=Single
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: firstname.lastname@example.org Phone no: +91 96545 76783 Web: https://growthplusreports.com/ Follow Us: LinkedIn | Twitter